Key result
A new combined pellet formulation of dipyridamole and aspirin provided extended and more uniform steady-state dipyridamole levels with fewer side effects compared to conventional products.
Why the study?
Does a combined dipyridamole and aspirin pellet formulation improve steady-state drug levels and reduce side effects compared to conventional products in humans?
Does a combined dipyridamole and aspirin pellet formulation improve steady-state drug levels and reduce side effects compared to conventional products in humans?
A new combined pellet formulation of dipyridamole and aspirin provides more uniform dipyridamole pharmacokinetics and fewer side effects compared to conventional products.
Answers are grounded in this paper and cite their sources.
Should not yet change antiplatelet prescribing; leaves open the value of pellet formulations for future randomized testing.
Hard capsules containing 150 mg dipyridamole and 100 mg aspirin containing pellets were compared in 12 humans against the equivalent dose of conventional products given twice daily. The new product gave extended and more uniform levels of dipyridamole in the steady-state, with a lower incidence of undesirable side-effects, whereas aspirin levels were similar. The new product also had acceptable long-term stability provided it was stored under cool conditions and low humidity.
No takes yet. Share an insight, caveat, or question.
Murtagh et al. (1996) studied this question. Combined dipyridamole and aspirin pellet formulation vs. Equivalent dose of conventional products given twice daily was evaluated on Steady-state levels of dipyridamole and aspirin, and incidence of side-effects. A new combined pellet formulation of dipyridamole and aspirin provided extended and more uniform steady-state dipyridamole levels with fewer side effects compared to conventional products.
Synapse has enriched 10 related papers. Consider them for comparative context: